TheDaoIndex KDAO2011
3 years 10 months ago
Withdrawing IL17i will more likely cause a relapse, but pts will respond when reintroduced -Dr Scher #PsA @rheumnow #acr22 #acrreview https://t.co/FvWVuQGJda
Dr. John Cush RheumNow
3 years 10 months ago
Dr. Sheila Reyes is back and covering #ACR22 as a RheumNow reporter. Follow @RHEUMarampa from real-time conference coverage! https://t.co/MeA2RggI9S
TheDaoIndex KDAO2011
3 years 10 months ago
Sialadenosis is a mimic of #sjogren - it related to fatty infiltration/metabolic syndrome. Correct underlying issue and pts will improve - Dr S McCoy @rheumnow #acrreview #acr22 https://t.co/bZPj1LmERs
Catherine Sims, MD DrCassySims
3 years 10 months ago
Wonderful slide by Dr. Sarah McCoy on #Sjogrens #ACR22 @RheumNow
Broad differential for these patients when they present in clinic:
📍Ask about:
🚬 habits
💊 meds
🍬 🩻history: #diabetes, past radiation exposure
🦠 infection (#HIV, #HCV)
🩸 #vitamin deficiency https://t.co/6Qo23lWBs4
After decades of having little else proven apart from glucocorticosteroids with which to treat polymyalgia rheumatica (PMR), evidence for steroid-sparing options has grown in recent years, and this crescendo is set to continue at ACR Convergence 2022 in Philadelphia, PA.
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as they will be discussed and mentioned throughout the meeting.
Abbvie
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022.
sheila RHEUMarampa
3 years 10 months ago
Dr. Coldiron (thru case examples) shares how the MSF works in providing medical care to pts in areas of conflict or crisis & how #climate change has also impacted health, including #Mentalhealth
#ACR22 @RheumNow @rheumarhyme https://t.co/gFuX4sL0WA
TheDaoIndex KDAO2011
3 years 10 months ago
50 yo hispanic male +MDA5 Ab w/ synovitis, skin lesions, neg ANA, normal CK, aldolase, +MDA5 Ab, Skin biopsy show changes c/w dermatomyositis. Failed MTX/MMF, no insurance. What is MDA5's role? Does race play a factor in Rx response? What is your next step? @rheumnow #ACR22 https://t.co/tGy2BH6y45
Janet Pope Janetbirdope
3 years 10 months ago
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow
TheDaoIndex KDAO2011
3 years 10 months ago
Dr. M Tikly share #rheum challenges & solutions in South Africa:
👉⬆️training to gen. practitioners & nurses, 👉estab outreach clinics
👉lobby local government/political groups
👉use of off-label drugs
👉engage pharma: free meds/clinical trials #ACR22 #GlobalHealth @rheumnow https://t.co/BX2qXk1usN
sheila RHEUMarampa
3 years 10 months ago
Dr. Tikly discusses the solutions to drug access challenges in South Africa in both state and private sectors 👇
🔸Off label use, buyouts, price⬇️, advocacy...
Highly relatable because these are similar challenges we face in the PH @rheumarhyme @doktora_ging
#ACR22 @rheumnow https://t.co/ajshylgtIE
David Liew drdavidliew
3 years 10 months ago
Finally we're starting to get therapies for polymyalgia rheumatica!
The best of PMR therapeutics coming up at #ACR22 (and catch it all @RheumNow): https://t.co/lUPICA3Mim
Dr. John Cush RheumNow
3 years 10 months ago
#ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
New research being presented at #ACR22, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with combo DMARDSs.
https://t.co/qmfnEvDedA https://t.co/VhkYlZJG3s
